Enanta Pharmaceuticals Inc

ENTA11 Dec 2024
Healthcare
$8.94
-0.03 (-3.36%)
Lowest Today
$8.57
Highest Today
$9.59
Today’s Open
$8.94
Prev. Close
$8.94
52 Week High
$17.8
52 Week Low
$7.58
To Invest in Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

Healthcare
ENTA11 Dec 2024
-0.03 (-3.36%)
1M
3M
6M
1Y
5Y
Low
$8.57
Day’s Range
High
$9.59
8.57
52 Week Low
$7.58
52-Week Range
52 Week High
$17.8
7.58
1 Day
-
1 Week
+1.05%
1 month return
-21.15%
3 month return
-28.66%
6 month return
-35.74%
1 Year return
-4.96%
3 Years return
-88.16%
5 Years return
-86.61%
10 Years return
-
Institutional Holdings
Farallon Capital Management, L.L.C.
9.95
Vanguard Group Inc
9.35
BlackRock Inc
8.72
Krensavage Asset Management, LLC
7.07
Morgan Stanley - Brokerage Accounts
5.2
Armistice Capital, LLC
4.72
Marshall Wace Asset Management Ltd
4.01

Market Status

Fundamentals
Market Cap
189.48 mln
PB Ratio
1.32
PE Ratio
0
Enterprise Value
-23.16 mln
Total Assets
376.65 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Organisation
Enanta Pharmaceuticals Inc
Employees
145
Industry
Biotechnology
CEO
Dr. Jay R. Luly Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities